BRPI9510423B8 - formulação lipossomal multilamelar de baixa rigidez, e, formulação antiinfecciosa - Google Patents

formulação lipossomal multilamelar de baixa rigidez, e, formulação antiinfecciosa Download PDF

Info

Publication number
BRPI9510423B8
BRPI9510423B8 BRPI9510423A BRPI9510423A BRPI9510423B8 BR PI9510423 B8 BRPI9510423 B8 BR PI9510423B8 BR PI9510423 A BRPI9510423 A BR PI9510423A BR PI9510423 A BRPI9510423 A BR PI9510423A BR PI9510423 B8 BRPI9510423 B8 BR PI9510423B8
Authority
BR
Brazil
Prior art keywords
formulation
infectious
low rigidity
liposomal formulation
multilamellar liposomal
Prior art date
Application number
BRPI9510423A
Other languages
English (en)
Inventor
Beaulac Christian
Lagace Jacqueline
Clement-Major Sébastien
Original Assignee
Univ Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23430112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9510423(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Montreal filed Critical Univ Montreal
Publication of BRPI9510423B8 publication Critical patent/BRPI9510423B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)

Abstract

"formulação lipossomal multilamelar de baixa rigidez processo de tratamento ou de profilaxia de uma infecção bacteriana em um animal e de uma variante mucoíde da mesma, uso da formulação lipossomal e formulação antibacteriana". a invenção refere-se a uma formulação lipossomal contendo pelo menos um agente terapêutico tal como um antibiótico e a um processo de tratamento de infecções bacterianas pela administração de uma tal formulação. é fornecida uma formulação lipossomal multilamelar de baixa rigidez, isenta de colesterol, compreendendo um lipídeo neutro, um lipídeo aniônico e pelo menos um agente terapêutico, em que a formulação lipossomal melhora a penetração do agente terapêutico em uma célula bacteriana. uma combinação de lipídeo preferida é dipalmitoilfosfatidilcolina (dppc): dimiristoilfosfatidil-glicerol (dmpg) a uma proporção de 10:1 até 15:1, com concentração total de lipídeo na faixa de 5 até 85 mm.
BRPI9510423A 1994-12-23 1995-12-22 formulação lipossomal multilamelar de baixa rigidez, e, formulação antiinfecciosa BRPI9510423B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/363,416 US5662929A (en) 1994-12-23 1994-12-23 Therapeutic liposomal formulation
PCT/CA1995/000713 WO1996019972A1 (en) 1994-12-23 1995-12-22 Low rigidity liposomal antibacterial composition

Publications (1)

Publication Number Publication Date
BRPI9510423B8 true BRPI9510423B8 (pt) 2019-11-05

Family

ID=23430112

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9510423-2A BR9510423A (pt) 1994-12-23 1995-12-22 Formulação lipossomal multilamelar de baixa rigidez processo de tratamento ou de profilaxia de uma infecção bacteriana em um animal e de uma variante mucoìde da mesma, uso da formulação lipossomal antibacteriana
BRPI9510423A BRPI9510423B8 (pt) 1994-12-23 1995-12-22 formulação lipossomal multilamelar de baixa rigidez, e, formulação antiinfecciosa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR9510423-2A BR9510423A (pt) 1994-12-23 1995-12-22 Formulação lipossomal multilamelar de baixa rigidez processo de tratamento ou de profilaxia de uma infecção bacteriana em um animal e de uma variante mucoìde da mesma, uso da formulação lipossomal antibacteriana

Country Status (14)

Country Link
US (1) US5662929A (pt)
EP (1) EP0806941B1 (pt)
JP (1) JP4523078B2 (pt)
KR (1) KR100438657B1 (pt)
AT (1) ATE235229T1 (pt)
AU (1) AU702463B2 (pt)
BR (2) BR9510423A (pt)
CA (1) CA2206296C (pt)
DE (1) DE69530124T2 (pt)
DK (1) DK0806941T3 (pt)
ES (1) ES2196092T3 (pt)
NZ (1) NZ297364A (pt)
PT (1) PT806941E (pt)
WO (1) WO1996019972A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6443949B2 (en) * 1997-03-13 2002-09-03 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6511477B2 (en) * 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6054133A (en) * 1997-07-10 2000-04-25 The Regents Of The University Of California Anti-microbial targeting for intracellular pathogens
US6613352B2 (en) * 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US6365138B1 (en) * 2000-04-07 2002-04-02 The Regents Of The University Of California Compositions for metabolic protection and repair of lips
WO2001097859A1 (en) * 2000-06-16 2001-12-27 Sloan-Kettering Institute For Cancer Research Liposomal encapsulation of chelated actinium-225 and uses thereof
CA2433280C (en) 2000-12-27 2010-09-21 Salus Pharma, Inc. Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
US7214364B2 (en) 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
JP2005525375A (ja) * 2002-03-05 2005-08-25 トランセイブ， インク． 生物活性物質をリポソーム又は脂質複合体内に封入する方法
DE10214983A1 (de) * 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
ES2439727T3 (es) * 2002-10-29 2014-01-24 Insmed Incorporated Liberación sostenida de antiinfectantes
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
DE10255285A1 (de) * 2002-11-26 2004-06-03 Mcs Micro Carrier Systems Gmbh Selbst formende Phospholipid-Gele
ES2281021T3 (es) * 2003-10-15 2007-09-16 Pari Pharma Gmbh Formulacion liquida que contiene tobramicina.
US20050214224A1 (en) * 2003-11-04 2005-09-29 Nektar Therapeutics Lipid formulations for spontaneous drug encapsulation
CA2838111C (en) 2005-12-08 2016-01-19 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
WO2013009761A1 (en) * 2011-07-13 2013-01-17 The Foundry, Llc Methods and apparatus for delivering a therapeutic agent to nasopharyngeal mucosa targets
DE102009031274A1 (de) 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
CN108743537B (zh) 2012-05-21 2021-06-11 英斯麦德公司 治疗肺部感染的系统
CN104884047A (zh) 2012-11-29 2015-09-02 英斯梅德股份有限公司 稳定的万古霉素制剂
MX2016014921A (es) 2014-05-15 2017-07-28 Insmed In Incorporated Metodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
EP3177269A4 (en) 2014-08-04 2018-02-28 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into lipid vesicles
ES2574615B1 (es) * 2014-12-19 2017-07-24 Biopraxis Research Aie Nanopartícula lipídica de tobramicina
CA3075097A1 (en) * 2017-10-02 2019-04-11 Aridis Pharmaceuticals, Inc. Compositions and methods against p. aeruginosa infections
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
CN117017999A (zh) * 2023-09-20 2023-11-10 四川大学 一种夫西地酸磷脂复合物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4981692A (en) * 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
US4952405A (en) * 1988-10-20 1990-08-28 Liposome Technology, Inc. Method of treating M. avium infection
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
PT100486B (pt) * 1992-05-14 1999-07-30 Ineti Inst Nac Engenh E Tecnol Aminoglucosidos lipossomais com altas eficacia de encapsulacao e actividade terapeutica, nomeadamente a netilmicina, e processo para a sua preparcao
AU3244393A (en) * 1992-12-02 1994-06-22 Vestar, Inc. Antibiotic formulation and process

Also Published As

Publication number Publication date
WO1996019972A1 (en) 1996-07-04
NZ297364A (en) 2000-01-28
ES2196092T3 (es) 2003-12-16
CA2206296A1 (en) 1996-07-04
BR9510423A (pt) 2003-01-07
ATE235229T1 (de) 2003-04-15
JP4523078B2 (ja) 2010-08-11
KR100438657B1 (ko) 2004-08-18
US5662929A (en) 1997-09-02
AU4251096A (en) 1996-07-19
EP0806941B1 (en) 2003-03-26
EP0806941A1 (en) 1997-11-19
AU702463B2 (en) 1999-02-25
DE69530124T2 (de) 2004-02-05
DK0806941T3 (da) 2003-07-21
KR980700062A (ko) 1998-03-30
MX9704679A (es) 1998-07-31
CA2206296C (en) 2007-05-22
PT806941E (pt) 2003-08-29
DE69530124D1 (de) 2003-04-30
JPH10511363A (ja) 1998-11-04

Similar Documents

Publication Publication Date Title
BRPI9510423B8 (pt) formulação lipossomal multilamelar de baixa rigidez, e, formulação antiinfecciosa
MXPA02002895A (es) Tratamiento topico de infecciones por estreptococcus.
AU6339599A (en) Quinoline derivatives and their use as antibacterial agents
MXPA03000708A (es) Aminopiperidin quinolinas y sus analogos azaisostericos con actividad antibacteriana.
ES2188652T3 (es) Sistema de direccionado de farmacos, metodos de fabricacion y uso del mismo.
BR0013010A (pt) Formulação de cloreto de sódio de moxifloxacina
AU3902299A (en) Methods of treating microbial infection and therapeutic formulations therefor
IL151628A0 (en) Combination therapies with vascular damaging activity
HUP0004579A2 (hu) Antibakteriális hatású, a 3'-N-pozícióban módosított szerkezetű 6-0-szubsztituált-eritromicin-ketolid-származékok és ezeket tartalmazó gyógyszerkészítmények
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
WO2000012049A3 (en) A method for the treatment of staphylococcal disease
TR199900661T2 (xx) Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m�
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
DK1135020T3 (da) Bipest-behandlinger
WO1999012552A8 (en) 9a-AZALIDES AS VETERINARY ANTIMICROBIAL AGENTS
PL330597A1 (en) Transcutaneous systems containing two active ingredients in separate compartments, method of obtaining them and their application as therapeutic agents
EP1510214A3 (en) 8a-azalides as veterinary antimicrobial agents
WO2000041473A3 (de) Verwendung von 3-isoxazolidinonen und hydroxylaminsäuren zur behandlung von infektionen
ES2086518T3 (es) Compuesto farmaceutico con accion cicatrizante.
HUP0203876A2 (hu) Topikális alkalmazású gyógyszerkombinációk
UA39988C2 (uk) Антимікробний засіб" асперсепт" та спосіб лікування та профілактики інфекційних уражень шкіри за допомогою цього засобу
EP1779853A3 (en) 9a-azalides as veterinary antimicrobial agents
UA34392A (uk) Спосіб лікування гінгівіту
UA28428A (uk) Лікарський засіб, що має антивірусну та антимікробну активність
MX9708385A (es) Derivados novedosos de tetraciclina, composiciones que los contienen, y el uso de las mismas.